Leucovorin Starting Dosage for 13-Year-Old Male, 92 lbs
For this 13-year-old male weighing 42 kg (92 lbs), the starting dose of leucovorin is 15 mg/m² every 6 hours by IV or IM injection, which translates to approximately 20-22 mg per dose based on an estimated body surface area of 1.4 m². 1
Context-Dependent Dosing Algorithm
The appropriate leucovorin dose depends critically on why this patient is receiving it:
For High-Dose Methotrexate (HDMTX) Rescue
Initial dosing:
- Standard starting dose: 15 mg/m² IV or IM every 6 hours 1
- For a 42 kg adolescent with BSA ~1.4 m²: approximately 21 mg per dose
- Timing: Start 24 hours after methotrexate infusion begins (for rapid infusion <6 hours) or 36-44 hours after start (for 24-hour infusion regimen) 1
- Route: IV or IM only—avoid oral administration due to chemotherapy-induced GI dysfunction and decreased bioavailability 1
Dose adjustment based on methotrexate levels at 42-48 hours:
The 2022 Chinese Pharmacological Society guideline provides a clear escalation strategy 1:
- MTX 0.2-1.0 μmol/L: Continue 15 mg/m² q6h (~21 mg per dose)
- MTX 1.0-2.0 μmol/L: Increase to 30 mg/m² q6h (~42 mg per dose)
- MTX 2.0-3.0 μmol/L: Increase to 45 mg/m² q6h (~63 mg per dose)
- MTX 3.0-4.0 μmol/L: Increase to 60 mg/m² q6h (~84 mg per dose)
- MTX 4.0-5.0 μmol/L: Increase to 75 mg/m² q6h (~105 mg per dose)
- MTX >5.0 μmol/L: Dose = MTX concentration × weight in kg, q6h
The FDA label corroborates this approach, specifying 15 mg every 6 hours for normal methotrexate elimination, with escalation to 150 mg every 3 hours for delayed early elimination 2.
For Methotrexate Overdose or Impaired Elimination
Start immediately with 10 mg/m² (~14 mg) IV, IM, or PO every 6 hours until serum methotrexate <10⁻⁸ M 2. If 24-hour creatinine increases ≥50% or methotrexate levels remain dangerously elevated, escalate to 100 mg/m² (~140 mg) IV every 3 hours 2.
Critical Safety Considerations
Do NOT administer leucovorin intrathecally—this is explicitly contraindicated 2.
Infusion rate limits: When single doses exceed 160 mg, infuse over at least 1 hour to avoid calcium-related complications 2. For this patient's weight, this becomes relevant only at the highest rescue doses.
Monitoring requirements:
- Measure serum creatinine and methotrexate levels at least daily 2
- Continue leucovorin until methotrexate <0.05-0.2 μmol/L 1
- Monitor liver and kidney function throughout rescue 1
- Maintain urine pH ≥7.0 with hydration and alkalinization 2
Evidence Quality and Strength
The 2022 guideline from the British Journal of Clinical Pharmacology provides the most comprehensive, recent evidence for pediatric dosing 1. This is a strong recommendation based on low-quality evidence for the initial 15 mg/m² dose, with systematic review of 4 studies showing no difference in toxicity compared to higher doses (20-30 mg/m²). The dose adjustment strategy based on methotrexate levels is a weak recommendation based on expert opinion, adapted from pediatric ALL protocols.
The FDA label supports these recommendations but provides less granular guidance for dose escalation 2.
Common pitfall: Starting leucovorin too early antagonizes methotrexate's chemotherapeutic effect 1. Conversely, delaying beyond recommended timeframes increases toxicity risk. Adhere strictly to the timing protocols based on methotrexate infusion duration.
Formulation consideration: Use parenteral formulations exclusively during active chemotherapy due to GI toxicity and unreliable oral absorption 1. The evidence for autism treatment 3, 4 is irrelevant to this clinical scenario and should be disregarded.